The treatment of hyponatraemia using vasopressin antagonists

Experimental Physiology

Volumn 85 S, Issue SPEC. ISS., 2000, Pages

  Gross, Peter ^a   Palm, Catrin ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; FLUID BALANCE; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW;

EID: 0034026204     PISSN: 09580670     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-445x.2000.tb00030.x     Document Type: Review

References (26)

1. ABRAHAM, W. T., OREN, R. M. & SCHRIER, R. W. (1997). Effects of an oral nonpeptide, selective V2 receptor vasopressin antagonist in human heart failure. Abstract (183). World Congress of Neurohypophyseal Hormones, Montreal, Canada, August 8-12, 1997.
2. ARIEFF, A., KOZNIEWSKA, E., ROBERTS, T. P. L., VEXLER, Z. S., KANDA, F., KUCHARCZYK, J. (1993). Role of vasopressin in brain damage from hyponatremic encephalopathy. In Vasopressin, ed. GROSS, P., RICHTER, D. & ROBERTSON G. L., pp 243-260. John Libbey, Paris.
3. BERNAT, A., HOFFMANN, P., DUMAS, A., SERRADEIL-LE GAL, C., RAUFASTE, D. & HERBERT, J. M. (1997). V2 receptor antagonism of dDAVP-induced release of hemostasis factors in conscious dogs. Journal of Pharmacology and Experimental Therapeutics 282, 597-602.
4. BICHET, D. G., SZATALOWICZ, V., CHAIMOVITZ, C. & SCHRIER, R. W. (1982). Role of vasopressin in abnormal water excretion in cirrhotic patients. Annals of Internal Medicine 96, 413-417.
5. COUPET, J., MAZANDARANI, H., ALBRIGHT, J. D. & DUSZA, J. P. (1997). Characterization of VPA-985 as a specific, nonpeptide vasopressin V2 antagonist. Abstract (181), World Congress of Neurohypophyseal Hormones, Montreal, Canada, August 8-12, 1997.
6. FUJISAWA, G., ISHIKAWA, S., TSUBOI, Y, OKADA, K. & SAITO, T. (1993). Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney International 44, 19-23.
7. FUJITA, N., ISHIKAWA, S., SASKI, S., FUJIKAWA, G., FUSHIMI, K. & MARUMO, F. (1995). Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. American Journal of Physiology 269, F926-931.
8. GROSS, P., KETTELER, M., HAUSMANN, C., REINHARD, C., SCHÖMIG, A., HACKENTHAL, E. & RITZ, E. (1988). Role of diuretics, hormonal derangements, and clinical setting of hyponatremia in medical patients. Klinische Wochenschrift 66, 662-669.
9. GROSS, P., KETTELER, M., HENSEN, J., SCHOMIG, A. & RASCHER, W. (1991). Advanced heart failure: The possible role of endothelin in kidney failure; baroreceptor mechanism of vasopressin stimulation in advanced heart failure and hyponatremia. Zeitschrift fur Kardiologie 80, suppl. 8, 99-100.
10. GROSS, P., REIMANN, D., NEIDEL, J., DÖKE, C., PROSPERT, F. & DECAUX, G. (1998). The treatment of severe hyponatremia. Kidney International 53, suppl. 64, S6-11.
11. INOUE, T., OHNISHI, A., MATSUO, A., KAWAI, B., KUNIHIRO, N. & TADA, Y. (1998). Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clinical Pharmacology and Therapeutics 5, 561-570.
12. KENNEDY, P. G. E., MITCHELL, D. M. & HOFFBRAND, D. I. (1978). Severe hyponatremia in hospital inpatients. British Medical Journal 2, 1251-1253.
13. KUHN, K., REIMANN, D. & GROSS, P. (1998). Beneficial effects of V2-vasopressin antagonist (ANTAG) in the hyponatremia of clinical cardiac failure (CHF), SIADH and liver cirrhosis (CI). Kidney and Blood Pressure Research 21, 183.
14. NAITOH, M., RISVANIS, J., PHILLIPS, P. A., JOHNSTON, C. I. & BURRELL, L. M. (1997). Effects of chronic AVP V2 R blockade in congestive heart failure in sheep - comparison with chronic ACE inhibition. Abstract (187) World Congress of Neurohypophyseal Hormones, Montreal, Canada, August 8-12, 1997.
15. NAITOH, M., SUZUKI, H., MURAKAMI, M., MATSUMOTO, A., ARAKAWA, K. & ICHIHARA, H. (1994). Effect of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. American Journal of Physiology 267, H 2245-2254.
16. NISHIKIMI, T., KAWANO, Y., SAITO, Y. & MATSUOKA, H. (1996). Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. Journal of Cardiovascular Pharmacology 27, 275-282.
17. OKADA, K., ISHIKAWA, S., CARAMELO, C., TSAI, P. & SCHRIER, R. W. (1993). Enhancement of vascular action of arginine vasopressin by diminishing extracellular sodium concentration. Kidney International 44, 755-763.
18. ROBERTSON, G. L., AYCINENA, P. & ZERBE, R. L. (1982). Neurogenic disorders of osmoregulation. American Journal of Medicine 72, 339-353.
19. SAITO, T., ISHIKAWA, S., ABE, K., KAMOI, K., YAMADA, K. & SHIMIZU, K. (1997). Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Journal of Clinical Endocrinology and Metabolism 82, 1054-1057.
20. SCHRIER, R. W. (1988). Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy. New England Journal of Medicine 319, 1065-1072.
21. SEIBOLD, A., ROSENTHAL, W., BARBERIS, C. & BIRNBAUMER, M. (1993). Cloning of the human type-2-vasopressin receptor gene. Annals of the New York Academy of Sciences 689, 570-572.
22. SERRADEIL-LE GAL, C., LACOUR, C., VALETTE, G., GARCIA, G., FOULON, F. & GALINDO, G. (1996). Characterization of SR 121463A, a highly potent selective, orally active vasopressin V2-receptor antagonist. Journal of Clinical Investigation 98, 2729-2738.
23. SHIMIZU, K. (1995). Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans. Kidney International 48, 220-226.
24. TSUBOI, Y., ISHIKAWA, S., FUJISAWA, G., OKADA, K. & SAITO, T. (1994a). Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney International 46, 237-244.
25. TSUBOI, Y., ISHIKAWA, S., FUJISAWA, G., OKADA, K. & SAITO, T. (1994B). In vivo diuretic effect of a new non-peptide arginine vasopressin antagonist, OPC-31260, in conscious rats. Journal of Endocrinology 143, 227-234.
26. XU, D.-L., MARTIN, P. Y., OHARA, M., ST JOHN, J., PATTISON, T. & MENG, X. (1997). Upregulation of aquaporin-2 water channel expression in congestive heart failure rat. Journal of Clinical Investigation 99, 1500-1505.